Citadel Advisors LLC Reports New 2.4% Passive Stake in Allogene Therapeutics, Inc. (ALLO)

On May 15, 2026, Citadel Advisors LLC and associated reporting persons, including Kenneth Griffin, filed an amended Schedule 13G (Amendment No. 1) regarding their holdings in Allogene Therapeutics, Inc. (ALLO). Citadel Advisors LLC reported beneficial ownership of 5,795,242 shares of common stock, representing a 2.4% stake in the company. When aggregating all related entities, Kenneth Griffin is deemed to beneficially own 6,855,120 shares, or approximately 2.8% of the outstanding shares. This filing marks an increase from a previously reported 0% position, indicating a new significant passive investment. The reporting persons indicated that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing control of the issuer. All shares are held with shared voting and dispositive power. The calculation is based on approximately 243.8 million shares outstanding as of March 10, 2026.